Respiratory Syncytial Virus Vaccine Market 2026: Monitor Vaccine Development and Immunization Expansion Strategies
Respiratory Syncytial Virus Vaccine Market Size
The Business Research Company's Respiratory Syncytial Virus Vaccine Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035
LONDON, GREATER LONDON, UNITED KINGDOM, March 5, 2026 /EINPresswire.com/ -- The Respiratory Syncytial Virus Vaccine market is dominated by a mix of established pharmaceutical leaders and emerging biotechnology companies. Key players are focusing on innovative antiviral therapies, monoclonal antibodies, and vaccine-based approaches to improve prevention and treatment outcomes, particularly for infants, older adults, and immunocompromised populations. Understanding the competitive landscape is essential for stakeholders aiming to identify growth opportunities, advance clinical pipelines, and form strategic collaborations in this rapidly evolving market.
Which Market Player Is Leading the Respiratory Syncytial Virus Vaccine Market?
According to our research, GlaxoSmithKline plc led global sales in 2024 with 50% market share. The Arexvy division of the company is partially included in the respiratory syncytial virus vaccine market growth, provides a vaccine designed to prevent lower respiratory tract disease caused by RSV. Arexvy is approved for use in individuals aged 60 and older, as well as in those aged 50 through 59 who are at increased risk for RSV-related illness. The vaccine has demonstrated high efficacy, with clinical trials showing an 82.6% prevention rate against RSV-associated lower respiratory tract disease in adults aged 60 and older. Additionally, Arexvy has shown sustained efficacy over multiple RSV seasons, with 43.3% effectiveness in preventing severe illness in its third year following initial administration. GSK continues to explore the potential for expanded use of Arexvy in younger adults at increased risk for RSV.
How Concentrated Is the Respiratory Syncytial Virus Vaccine Market?
The market is concentrated, with the top 10 players accounting for 100% of total market revenue in 2024. This level of concentration reflects strong regulatory barriers, complex vaccine development requirements, and the need for extensive clinical and manufacturing capabilities. Leading vendors such as GlaxoSmithKline plc, Pfizer Inc., and Moderna Inc. dominate through established vaccine platforms, large-scale production capacity, and global distribution networks. As vaccination programs expand and next-generation respiratory vaccines advance, continued innovation and strategic collaborations are expected to further reinforce the leadership position of major pharmaceutical companies.
•Leading companies include:
oGlaxoSmithKline plc (50%)
oPfizer Inc. (48%)
oModerna Inc. (2%)
Request a free sample of the Respiratory Syncytial Virus Vaccine Market report:
https://www.thebusinessresearchcompany.com/sample_request?id=20195&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Mar_PR
Which Companies Are Leading Across Different Regions?
•North America: Pfizer Inc., GSK plc, Moderna, Inc., AstraZeneca PLC, Sanofi, Johnson & Johnson, Merck & Co., Inc. and Moderna Biotech Canada Ltd. are leading companies in this region.
•Asia Pacific: SK bioscience Co., Ltd., Pfizer Inc., Sanofi India Limited, GlaxoSmithKline Pharmaceuticals Limited, Serum Institute of India Private Limited, Biological E. Limited, Beijing Minhai Biotechnology Co., Ltd., Merck & Co., Inc., Moderna, Inc., CSPC Pharmaceutical Group Limited, Walvax Biotechnology Co., Ltd., and AIM Vaccines Co., Ltd. are leading companies in this region.
•Western Europe: Merck Sharp & Dohme Corp., GlaxoSmithKline plc, Sanofi S.A., PnuVax Incorporated, Johnson & Johnson, Pfizer Europe MA EEIG, CureVac N.V., Vicebio Limited, Pfizer Inc., and Novavax AB are leading companies in this region.
•Eastern Europe: Pfizer Polska Sp. z o.o., Sanofi S.A., Merck Sharp & Dohme Corp., GlaxoSmithKline plc, and Moderna, Inc. are leading companies in this region.
•South America: Pfizer Inc. is Pfizer Inc., GSK PLC is GlaxoSmithKline plc, AstraZeneca is AstraZeneca plc, and Sanofi SA are leading companies in this region.
What Are the Major Competitive Trends in the Market?
•Expansion of RSV vaccine approvals are transforming to include younger adults who are at increased risk of severe RSV disease due to underlying medical conditions.
•Example: Pfizer Inc. U.S. Food and Drug Administration (FDA) for Abrysvo (October 2024), for use in adults aged 18–59 years who are at increased risk for RSV lower respiratory tract disease.
•These innovation aims to expand RSV protection to a broader adult population and strengthen overall community immunity across the United States.
Which Strategies Are Companies Adopting to Stay Ahead?
•Expanding regulatory label and age indications to expand its operational capabilities
•Strategic partnerships, M&A & licensing deals to strengthen pipelines
•Diversifying vaccine portfolios to diverse patient needs
•Leveraging advanced technologies (AI/ML & Digital Tools) into their trial design and clinical development
Access the detailed Respiratory Syncytial Virus Vaccine Market report here:
https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-vaccine-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Mar_PR
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.
Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: info@tbrc.info
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
